No announcement yet.

Novel imiquimod nanovesicles for topical vaccination

  • Filter
  • Time
  • Show
Clear All
new posts

  • Novel imiquimod nanovesicles for topical vaccination

    Colloids Surf B Biointerfaces. 2018 Nov 15;174:536-543. doi: 10.1016/j.colsurfb.2018.11.031. [Epub ahead of print]
    Novel imiquimod nanovesicles for topical vaccination.

    Caimi AT1, Altube MJ1, de Farias MA2, Portugal RV2, Perez AP1, Romero EL1, Morilla MJ3.
    Author information


    Development of needle and pain free noninvasive immunization procedures is a top priority for public health agencies. In this work the topical adjuvant activity of the immunomodulator imiquimod (IMQ) carried by ultradeformable archaeosomes (UDA2) (nanovesicles containing sn-2,3 ether linked phytanyl saturated archaeolipids) was surveyed and compared with that of ultradeformable liposomes lacking archaeolipids (UDL2) and free IMQ, using the model antigen ovalbumin and a seasonal influenza vaccine in Balb/c mice. UDA2 (250  94 nm, -26  4 mV Z potential) induced higher IMQ accumulation in human skin and higher production of TNF-α and IL-6 by macrophages and keratinocytes than free IMQ and UDL2. Mixed with ovalbumin, UDA2 was more efficient at generating cellular response, as measured by an increase in serum IgG2a and INF-γ production by splenocytes, compared with free IMQ and UDL2. Moreover, mixed with a seasonal influenza vaccine UDA2 produced same IgG titers and IgG2a/IgG1 isotypes ratio (≈1) than the subcutaneously administered influenza vaccine. Topical UDA2 however, induced highest stimulation index and INF-γ levels by splenocytes. UDA2 might be a promising adjuvant for topical immunization, since it produced cell-biased systemic response with ≈ 13-fold lower IMQ dose than the delivered as the commercial IMQ cream, Aldara.


    Archaeolipids; Cellular response; Immunomodulator; Influenza vaccine

    PMID: 30500742 DOI: 10.1016/j.colsurfb.2018.11.031